Exploring the molecular mechanism of apigenin in treating bronchiectasis based on network pharmacology and molecular docking
Authors:
Open Access
- 7 November 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Abstract
Bronchiectasis is a complex, heterogeneous inflammatory chronic respiratory disease with an unknown etiology. In the context of increasingly severe drug resistance, there is an urgent need to explore new treatment strategies. Apigenin is a natural flavonoid compound with significant anti-inflammatory and antioxidant activities. This study aims to investigate the material basis and related pharmacological mechanisms of apigenin in the treatment of bronchiectasis using network pharmacology and molecular docking technology. The components and related targets of apigenin were searched using the TCMSP database. The SMILES numbers of each component of apigenin were obtained from the PubChem database, and the targets of each component were predicted using SwissTargetPrediction. All targets of the apigenin components were integrated. Targets related to bronchiectasis were retrieved and integrated from the GeneCards, TTD, and OMIM databases. The intersection targets of apigenin and bronchiectasis were identified using Venny 2.1.0 software. A protein-protein interaction (PPI) network was constructed and analyzed for topology using the String database platform and Cytoscape 3.10.3 software to screen out the main core targets. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the intersection targets using the David database. The binding activity between apigenin and the main core targets was tested using molecular docking technology. A total of 166 targets of apigenin and 2018 targets of bronchiectasis were screened, with 54 intersection targets identified between apigenin and bronchiectasis. The main core targets for apigenin in treating bronchiectasis were AKT1, MMP9, PARP1, SRC, and PTGS2. GO functional enrichment and KEGG pathway analyses yielded 380 GO entries (P < 0.05) and 111 signaling pathways (P < 0.05). These included 247 biological process entries, 35 cellular component entries, and 98 molecular function entries, primarily involving the PI3K-Akt signaling pathway, Chemokine signaling pathway, Lipid and atherosclerosis, Pathways in cancer, among others. Molecular docking results indicated that the binding energies between apigenin and these five core targets: AKT1, MMP9, PARP1, SRC, and PTGS2 were − 8.3 kcal/mol, -9.6 kcal/mol, -9.0 kcal/mol, -7.8 kcal/mol and − 8.8 kcal/mol, respectively, suggesting favorable binding activity between apigenin and the main core targets. Conclusion: From the perspective of network pharmacology and molecular docking technology, this study links apigenin to bronchiectasis at the molecular level for the first time. It systematically reveals the potential of apigenin to treat bronchiectasis through multiple targets and pathways. This provides a theoretical basis for in-depth exploration of the mechanism of apigenin in treating bronchiectasis and lays a foundation for subsequent experimental validation and clinical translation.Keywords
Funding Information
- the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region, self-funded projects (Z-A20240492, Z-A20240515)
- National Science Foundation of China (82104499, 82160783)
- Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation under (2023GXNSFBA026146)
- the Key Research Program of Guangxi Science and Technology Department (AB21196010)
This publication has 93 references indexed in Scilit:
- Quercetin attenuates Pseudomonas aeruginosa-induced acute lung inflammation by inhibiting PI3K/AKT/NF-κB signaling pathwayInflammopharmacology, 2024
- Calycosin prevents IL-1β-induced articular chondrocyte damage in osteoarthritis through regulating the PI3K/AKT/FoxO1 pathwayIn Vitro Cellular & Developmental Biology - Animal, 2022
- The effects of apigenin administration on the inhibition of inflammatory responses and oxidative stress in the lung injury models: a systematic review and meta-analysis of preclinical evidenceInflammopharmacology, 2022
- Bronchiectasis from 2012 to 2022Clinics in Chest Medicine, 2022
- Apigenin exerts chemopreventive effects on lung injury induced by SiO2 nanoparticles through the activation of Nrf2Journal of Natural Medicines, 2021
- Apigenin as an anticancer agentPhytotherapy Research, 2020
- Nrf2 signaling pathway: Pivotal roles in inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- Apigenin: A Promising Molecule for Cancer PreventionPharmaceutical Research, 2010
- Signal transduction via the stem cell factor receptor/c-KitCellular and Molecular Life Sciences, 2004
- The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-κB in inflammatory disordersCellular and Molecular Life Sciences, 2002